Bicycle Therapeutics plc — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; filed May 7, 2020. Bicycle is a clinical-stage biotechnology company with no approved products and no product-sale revenue. Its pipeline includes oncology candidates BT1718, BT5528 and BT8009, alongside partnered discovery programs.
Financial performance and liquidity
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Collaboration revenue | $1.1 million | $6.4 million |
| Research and development expense | $7.8 million | $6.3 million |
| General and administrative expense | $5.0 million | $3.4 million |
| Operating loss | $11.6 million | $3.3 million |
| Net loss | $11.3 million | $6.5 million |
| Basic and diluted loss per share | $0.63 | $7.80 |
| Operating cash flow | $21.2 million provided | $5.2 million used |
- Cash was $109.6 million at March 31, 2020, up from $92.1 million at year-end 2019. Management expected available cash to fund operating expenses and capital needs for at least 12 months from issuance of the interim statements.
- Current assets were $123.4 million and current liabilities $16.2 million. Total assets were $129.3 million; total liabilities were $47.5 million, including $34.3 million of deferred revenue. The company reported no debt outstanding.
- Operating cash flow benefited principally from a $30.1 million increase in deferred revenue, primarily reflecting Genentech collaboration payments. It should not be read as evidence of positive underlying operating earnings or recurring cash generation.
- Capital expenditures were $0.3 million; financing cash flow was approximately zero. Foreign-exchange movements reduced cash by $3.3 million.
- No product gross margin is reported because the company had no product sales. Net loss widened year over year; per-share loss is not directly comparable because the weighted-average share count changed substantially after the 2019 IPO and share reorganization.
Material changes versus Q1 2019
- Revenue fell $5.3 million, mainly because Q1 2019 included $5.3 million recognized when a Sanofi option expired. Sanofi revenue was zero in Q1 2020 following termination of that collaboration in 2019.
- Genentech contributed $0.7 million of recognized revenue in Q1 2020. The February 2020 collaboration provided $30 million upfront plus $1 million for a selected targeting arm; $29.0 million remained in deferred revenue at quarter-end.
- R&D expense rose $1.5 million, reflecting increased program and clinical/TICA development spending, personnel costs and share-based compensation, partly offset by higher R&D incentives.
- G&A expense increased $1.6 million, including higher share-based compensation, professional fees and public-company costs; favorable foreign-exchange effects partly offset the increase.
- Q1 2019 included $3.2 million of warrant-liability remeasurement expense; no such expense was recorded in Q1 2020.
Outlook, risks and unusual items
- Management expects operating losses and expenses to increase as clinical and preclinical programs advance. No specific revenue or earnings guidance was provided. The company expects to need substantial additional funding beyond its stated near-term cash runway.
- COVID-19 had limited financial impact at the filing date, but all UK clinical sites in the CRUK-sponsored BT1718 Phase I/IIa trial had paused new-patient enrollment. BT5528 enrollment and trial activity continued at US sites, though further disruption was possible. The company reported adequate expected global clinical-material supply for 2020 but warned of potential trial, supply-chain, partner and financing delays.
- On February 18, 2020, the Hague Court of Appeal ruled that Pepscan could terminate a patent license and enjoined BicycleRD from exploiting the licensed patents and related know-how worldwide, subject to a €25,000 daily fine for non-compliance. BicycleRD said it would comply and intended to appeal. The dispute concerns technology associated with BT1718 and a product licensed to Oxurion; related patent proceedings remain unresolved.
- Other notable exposures include clinical-development and regulatory uncertainty, reliance on CROs and contract manufacturers, foreign-exchange risk, and the possibility of further capital raises. The company reported no debt and no material change in contractual commitments during the quarter.
- Management stated disclosure controls were effective as of March 31, 2020, with no material change in internal control over financial reporting during the quarter.
Key investor verification points
- Track the duration and consequences of the BT1718 enrollment pause and whether COVID-19 disrupts BT5528 enrollment, trial execution or clinical supply.
- Review subsequent developments in the Pepscan appeal, injunction scope, related patent challenges and any effect on BT1718 or other programs.
- Confirm cash consumption and runway over subsequent quarters, separating collaboration cash receipts and deferred-revenue changes from recurring operating cash flows.
- Monitor Genentech option exercises, milestone conditions and revenue recognition, as well as the timing and durability of other collaboration income.
- Assess whether rising R&D and public-company costs, together with planned pipeline advancement, require additional financing before the stated runway ends.